摘要
胃癌的治疗效果不佳,提倡个体化治疗,生物标记物是筛选个体化治疗的重要手段。人类表皮生长因子受体2(human epidermal growth factor receptor 2,Her-2)在胃癌组织中高表达,与胃癌的预后相关,可指导晚期胃癌的分子靶向治疗。Her-2状态还可能和晚期胃癌患者化疗敏感性相关,并可指导胃癌术后辅助治疗获益人群的筛选。
The treatment effect of gastric cancer is poor currently. We promote the individualized treatment. Biomark- ers are important means of screening individualized treatment. Human epidermal growth factor receptor 2 （ Her - 2） is increased in gastric cancer tissue. It is associated with the prognosis of gastric cancer, can guide the molecular target therapy for advanced gastric cancer. Moreover, Her - 2 status may be related to chemotherapeutic sensitivity and screen the gastric cancer patients who can be benefited from postoperative adjuvant therapy.
出处
《现代肿瘤医学》
CAS
2015年第8期1139-1141,共3页
Journal of Modern Oncology
关键词
人类表皮生长因子受体2
胃癌
预后
靶向治疗
辅助治疗
human epidermal growth factor receptor 2
gastric cancer
prognosis
targeted therapy
adjuvant therapy
